In summary, besides treatment protocol, early tumour stage (cT1-2), tumour length ≤ 3.5 cm, normal routine blood counts, and CEA can assist in predicting pCR and, ultimately, cCR state in a setting before neoadjuvant treatment initiation. This evidence concerns the gene CEACAM5 and neoplasm.